Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2023 | Open label extension of prasinezumab in Parkinson’s disease: 1 year updates

Prasinezumab is a monoclonal antibody that binds to aggregated α-synuclein and was the compound tested in the recent Phase II PASADENA study (NCT03100149). This was a randomized, double-blind, placebo-controlled study evaluating the efficacy of prasinezumab in participants with early-stage Parkinson’s disease (PD). Participants were treated with monthly
prasinezumab for three years or placebo for one year followed by prasinezumab for two years (delayed start arm). Previous data from the end of the three-year phase showed that the early start group had lower rates of motor progression and motor complications, compared to the delayed start arm. Gennaro Pagano, MD, MSc, PhD, Roche Pharma Research & Early Development, Basel, Switzerland, speaks about the subsequent open label extension study of this compound, one year in. The results so far support previous data, showing that the patients treated with prasinezumab for three years were at a lower risk of developing motor complications compared to those who were treated for two years. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Pagano is a full-time employee and shareholder at F. Hoffmann – La Roche Ldt.